 This is for subjects with metastatic Renal Cell Cancer RCC. There are four Food and Drug Administration FDA approved drugs for first-line therapy of Renal Cell Cancer RCC and two for second-line therapy. Each of these drugs targets a specific molecular pathway. At present oncologists select therapy based on current guidelines. There is a new method for trying to use biomarker information from the subjects tumor to select the best drug to treat the subject. This process is investigational, which is why this study is being done. 